Four months af­ter pa­tient death, FDA's hold lift­ed on Al­ny­lam's fi­tusir­an

The FDA has lift­ed its clin­i­cal hold on Al­ny­lam’s blood clot­ting drug fi­tusir­an fol­low­ing a four-month stand­still.

The com­pa­ny’s Phase II and Phase III stud­ies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER